Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. - Wikidata - wikimedia - TriplyDB

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

http://www.wikidata.org/entity/Q34188205

about

Indacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for chronic obstructive pulmonary disease Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease Health-related quality of life measurement in asthma and chronic obstructive pulmonary disease: review of the 2009-2014 literature Positioning new pharmacotherapies for COPD Ten years of tiotropium: clinical impact and patient perspectives Improving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterol A year in review: new drugs for older adults in 2011 Postapproval Development Options in COPD: A Case Study in Value-Based Healthcare Systems.Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol.Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis COPD: maximization of bronchodilation.Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysis Influence of indacaterol on daily physical activity in patients with untreated chronic obstructive pulmonary disease Safety of indacaterol in the treatment of patients with COPD.Comparison of clinical efficacy and safety between indacaterol and tiotropium in COPD: meta-analysis of randomized controlled trials Effects of indacaterol versus tiotropium on respiratory mechanics assessed by the forced oscillation technique in patients with chronic obstructive pulmonary disease.A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study.Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trial The role of bronchodilator treatment in the prevention of exacerbations of COPD.Indacaterol in chronic obstructive pulmonary disease: an update for clinicians.Pharmacotherapies for COPD.Indacaterol: a comprehensive review.Chronic obstructive pulmonary disease in China: the potential role of indacaterol Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations.A new class of bronchodilator improves lung function in COPD: a trial with GSK961081.Differences in physical activity according to mMRC grade in patients with COPD Effects of indacaterol versus tiotropium on exercise tolerance in patients with moderate COPD: a pilot randomized crossover study.Role of indacaterol, a once-daily bronchodilator, in chronic obstructive pulmonary disease.Efficacy of indacaterol on quality of life and pulmonary function in patients with COPD and inhaler device preferences.Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.Immediate salbutamol responsiveness does not predict long-term benefits of indacaterol in patients with chronic obstructive pulmonary disease.Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterol.Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease.Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease.Indacaterol: a new long-acting β2-agonist in the management of chronic obstructive pulmonary disease.Future of chronic obstructive pulmonary disease management.Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective.Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review

P2860

Q24186652-67C03800-3489-48DD-957C-E90079EBC909 Q24197853-66CFD6A7-AADB-4D49-AD27-426598E48C36 Q24200476-8F615272-4E09-4905-BF41-0994A6DAAFA9 Q26765780-75BEF1C8-056B-4BA0-BFC7-5A31C9E7FCEC Q26798659-D3F8BD7E-D4C0-4B1F-A29F-6A56EB287F48 Q26823682-0E0957AB-CC84-40BF-8809-CB1538C29014 Q26851664-7E451D4E-200D-482B-B10F-C34751ACBBB0 Q33637890-83A9381F-F478-41C8-9F5F-94586AB9871E Q33932267-932A4240-0D59-4E1F-A44E-1FFAB1EEA090 Q34011640-01557E98-2976-4DB7-AB30-CC81071EA8BD Q34049219-C338C81A-CA3F-44E2-B7B2-4B889272C53D Q34316776-796ED21F-66CE-43A7-9030-899E1536AE56 Q34436393-F93EFD29-BB4C-434E-9AD8-19875201B697 Q34962838-41B365E7-51EF-4B0F-A86A-D1F43CEC6781 Q35161561-C7916CD4-A91B-4A5C-80BF-797556DB6917 Q35268351-38DAE607-2809-451B-AC51-19B20200F99B Q35584046-9741442A-5D95-4236-8757-71DD41042518 Q35766357-6AD8429F-EE85-4561-8F55-F89382E5006F Q35816973-3CEA7BF6-9D79-4B5C-A2B0-D67038A77A86 Q36072399-CA05489B-D1AF-4E85-B30D-138E2C2239B1 Q36438669-03762F3C-78F2-40EB-958B-C82E2FE82A88 Q36443777-18105A70-18E7-4428-BC29-1F8683C9AE9D Q36843717-F9F54D97-3553-4601-865E-CCCBD10FCAAC Q37057061-180B9C62-7A6D-452C-9A5C-706F6ABC9D17 Q37128034-5FC8BD7C-BF52-49F8-80AA-000072EB5C13 Q37177278-D85F85B3-A506-4E24-AEF2-3B92C8013DD8 Q37209304-7F3E6EB3-E206-4DEF-BC7A-3FA278C4B39C Q37265683-2576C8C3-B5A6-48DC-BBE9-93325049B56D Q37392356-DAFE8F34-4635-406C-BB78-8C749DE15C91 Q37457359-559A6499-FCCE-45E7-ACD3-07D6CBEEEABF Q37524951-5E752E56-74F8-4E77-9CBB-A10EEBF6F885 Q37614103-47081CB6-B93C-4200-B151-83E88158E600 Q37615959-5888DD8E-30DF-40B6-A95D-AB1FB921799D Q37911291-EB9B5174-EEED-4462-9EF1-7691ED324927 Q37973132-07D1AAD4-7FE1-487E-A53A-C1E2152694D2 Q37987211-AEB9226E-5E0F-4251-97E5-CED03889F107 Q37999465-3643AC9A-BB3F-44C4-A460-5038EFC2F8FB Q38025725-8D2814A4-1C35-4465-BD6C-58B2E5002A35 Q38072277-B572CCF3-BF9A-4C40-A3D6-09FB2DAB6362 Q38148145-6D711355-D5F1-4676-9BBC-0F58AD4308DD

P2860

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

http://www.wikidata.org/entity/Q34188205

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

@ast

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

@en

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

@nl

type

label

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

@ast

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

@en

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

@nl

prefLabel

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

@ast

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

@en

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

@nl

P1433

Q34188205-2123AB99-ABDA-4126-82B9-7467494F4F6B

P1476

Q34188205-53C504E9-7900-4521-8125-B907B72F527D

P2093

Q34188205-0E148C5F-173A-4CA8-BE09-057896487415

Q34188205-16B08B98-556F-45EF-8BC3-8770DCDC9231

Q34188205-1CC6C7F9-E040-44B3-A794-E3D05C76FFDB

Q34188205-211C9A4A-2940-4B92-BEF1-D4CE4F7354CE

Q34188205-40110415-8F97-4007-9AD3-A95AED7ECA4B

Q34188205-8E4BC567-AB88-42A2-98C6-E7020F041562

Q34188205-E0D04A5A-C2F8-4D9E-9DEA-873B9E49A0D3

Q34188205-FB9E7934-E9B6-4FC3-B806-62D47E7FAB1D

P304

Q34188205-1A7825B1-BF7A-404E-8C9B-B1AEDC3F038D

P31

Q34188205-9904D2E3-9007-4F04-8CA7-312E49CB3E94

P356

Q34188205-142A3FA2-3074-40DF-B062-698BA0E6C346

P433

Q34188205-7C6561F7-73C9-42A6-A47A-465C7A6A3B71

P478

Q34188205-5F800A7D-4E79-42C6-8A68-94AEB6B63DD2

P577

Q34188205-DA7B5BD1-D10E-4D3E-A6FF-716FC42E7D27

P5875

Q34188205-FB55CBB2-A301-4CBF-8F27-EADB08EC0EB9

P698

Q34188205-4A877022-1BD7-4D22-80A5-060C8FC74389

P921

Q34188205-E2FECF70-A826-43AA-92D6-55A50A602615

P356

09031936.00191810

P1433

European Respiratory Journal

P1476

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

@en

P2093

B Kramer

http://www.w3.org/2001/XMLSchema#string

C Amos

http://www.w3.org/2001/XMLSchema#string

C Disdier

http://www.w3.org/2001/XMLSchema#string

C Lassen

http://www.w3.org/2001/XMLSchema#string

INTENSITY study investigators

http://www.w3.org/2001/XMLSchema#string

L J Dunn

http://www.w3.org/2001/XMLSchema#string

M Henley

http://www.w3.org/2001/XMLSchema#string

R Buhl

http://www.w3.org/2001/XMLSchema#string

P304

797-803

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1183/09031936.00191810

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51174761

http://www.w3.org/2001/XMLSchema#string

P698

21622587

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease